Clinical Trial Update: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial update for Rebif in relapsing multiple sclerosis; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2018-09-20